Globeflex Capital L P Increases Stock Position in Bioventus Inc. $BVS

Globeflex Capital L P raised its stake in Bioventus Inc. (NASDAQ:BVS) by 59.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 123,052 shares of the company’s stock after acquiring an additional 45,936 shares during the period. Globeflex Capital L P’s holdings in Bioventus were worth $1,123,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in the company. Marshall Wace LLP increased its position in shares of Bioventus by 0.4% during the fourth quarter. Marshall Wace LLP now owns 288,900 shares of the company’s stock worth $2,149,000 after purchasing an additional 1,281 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Bioventus by 7.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock valued at $211,000 after purchasing an additional 1,538 shares during the period. Mercer Global Advisors Inc. ADV boosted its position in shares of Bioventus by 16.2% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock valued at $101,000 after purchasing an additional 1,887 shares during the period. Deutsche Bank AG grew its stake in Bioventus by 8.2% during the 4th quarter. Deutsche Bank AG now owns 25,138 shares of the company’s stock worth $187,000 after buying an additional 1,908 shares during the last quarter. Finally, Engineers Gate Manager LP increased its position in Bioventus by 6.0% during the fourth quarter. Engineers Gate Manager LP now owns 68,889 shares of the company’s stock worth $513,000 after buying an additional 3,909 shares during the period. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Bioventus Stock Performance

NASDAQ BVS opened at $11.63 on Thursday. The firm has a market cap of $971.57 million, a P/E ratio of 28.37, a P/E/G ratio of 1.51 and a beta of 0.65. Bioventus Inc. has a 52-week low of $5.81 and a 52-week high of $12.53. The business’s 50-day moving average price is $9.97 and its 200 day moving average price is $9.24. The company has a quick ratio of 1.13, a current ratio of 1.69 and a debt-to-equity ratio of 1.08.

Bioventus (NASDAQ:BVS) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.09 by $0.06. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.The firm had revenue of $132.09 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, equities research analysts expect that Bioventus Inc. will post 0.79 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on BVS. Weiss Ratings reiterated a “hold (c)” rating on shares of Bioventus in a research note on Tuesday, June 2nd. Barrington Research restated an “outperform” rating and set a $14.00 target price on shares of Bioventus in a research report on Tuesday, June 30th. CJS Securities initiated coverage on shares of Bioventus in a report on Friday, March 27th. They issued a “market outperform” rating and a $14.00 target price on the stock. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $15.00 price target on shares of Bioventus in a research report on Tuesday, June 16th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $14.75.

Bioventus Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.